Physician profile
Steven Jon Nelson
NPI 1558327908
$1,627.04
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $488 · 2021: $17.47 · 2022: $138 · 2023: $55.60 · 2024: $19.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $548.88 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.91 | 2019 | |
| Lilly USA, LLC | $133.25 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $119.34 | 2019 | |
| Merck Sharp & Dohme LLC | $100.87 | 2019-2020 | |
| Pfizer INC. | $91.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $61.65 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $58.16 | 2019 | |
| Antares Pharma, INC. | $53.36 | 2020 | |
| Allergan, INC. | $50.59 | 2019-2020 | |
| Abbvie INC. | $35.52 | 2019-2022 | |
| Amgen INC. | $21.19 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.77 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.33 | 2019 | |
| Alfasigma USA, INC. | $13.12 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $11.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.